Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients ...
Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms ...
(PDF) A phase I dose-escalation study of IMAB362 (Zolbetuximab) in ...
PK parameters of IMAB362 at different doses in patients with advanced ...
Zolbetuximab | 1496553-00-4 | AbMole | IMAB362
Table 2 from A phase I dose-escalation study of IMAB362 (Zolbetuximab ...
Mechanism of action of claudiximab (IMAB362) | Download Scientific Diagram
FDA Approves Zolbetuximab (a CLDN18.2-directed Cytolytic Antibody) to ...
Zolbetuximab (IMAB362) | Claudin-18.2 Inhibitor | MedChemExpress
Main characteristics of claudin18.2 and zolbetuximab. ADCC, activate ...
Claudin 18.2(CLDN18.2)靶向药单抗Zolbetuximab(佐贝妥昔单抗、IMAB362)在日本上市,用于治疗CLDN18 ...
靶向Claudin18.2靶点新药新疗法在中美两国纷纷获批临床试验,Claudin 18.2这个靶点究竟有什么潜力?-无癌家园
Full article: Development and Characterization of 4A7: A High-Affinity ...
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX ...
Claudin 18.2靶点竞争格局和新机会：CAR-T、双抗、ADC、CARVac_抗体
(PDF) Anti-claudin 18.2 antibody as new targeted therapy for advanced ...
Claudin-18：肿瘤学的治疗靶点 - 每日生物评论
Full-length membrane protein services
【Zolbetuximab 】於胃腸道腺癌和胰腺腫瘤研究(Claudin 18.2)
Zolbetuximab临床试验,Zolbetuximab(IMAB362)治疗胃和胃食管交界(GEJ)腺癌的临床试验研究
Frontiers | CLDN18.2: a potential nanotherapeutic target for ...
胃癌潜力靶点：Claudin 18.2 - 知乎
徐瑞华教授：改变晚期胃癌治疗标准，Claudin 18.2 单抗登上 ASCO_腾讯新闻
2024年10月18日FDA批准了全球首款CLDN18.2(Claudin 18.2)靶向药佐贝妥昔单抗(Zolbetuximab ...
LBA-06 IMAB362: a novel immunotherapeutic antibody targeting the tight ...
Comprehensive clinical and molecular characterization of claudin 18.2 ...
CLDN18.2 bispecifics available to license
Claudin18.2蛋白的靶向治疗 - 知乎
Targeting Claudin18.2 for cancer theranostics: From molecular imaging ...
肿瘤免疫靶点 | Claudin18.2 - 知乎
Novel Targeted Drug Approved for Stomach Cancers | MedPage Today
Anti-Claudin 18_2 antibody and application thereof - Eureka | Patsnap
Clinical trials associated with IMAB362. | Download Scientific Diagram
Claudin 18.2：癌症治疗的新靶点医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
重磅靶点Claudin18.2旋风来袭 ，肿瘤治疗新希望 - 知乎
实力靶点CLDN18.2：群狼环伺，谁主沉浮？ Claudin（CLDN）蛋白是上皮细胞紧密连接的重要组成之一，其异常表达或失调会导致上皮细胞 ...
Claudin18.2靶点之争：安斯泰来搭台，国内药企唱戏医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Astellas首个Claudin18.2抗体三期临床成功 11月17日，Astellas宣布旗下Claudin18.2抗体 ...
CLDN18.2单抗Zolbetuximab获批上市！用于治疗胃癌！-印塔健康官网
CLDN18.2丨肿瘤免疫治疗赛道的黑马 - 知乎
Claudin18.2 ADC深度梳理医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
胃癌靶向治疗的曙光——Claudin18.2
Various clinical trials involving claudiximab (IMAB362) | Download Table
Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo ...
针对Claudin18.2 这个肿瘤新靶点的新疗法效果喜人！首个III期临床试验结果呈阳性！ - 知乎
新品来袭：荧光融合的Claudin18.2全长膜蛋白 - 知乎
上新 | 突破跨膜蛋白制备技术难题，Claudin18.2-VLP全长跨膜蛋白隆重亮相！-技术前沿-资讯-生物在线
Claudin18.2 Targeted Therapies In Cancer.pdf
Preclinical characterization of IMAB362-vcMMAE, an anti-CLDN18.2 ...
zolbetuximab (IMAB362) / Astellas
安斯泰来：Claudin18.2抗体三期临床成功 Armstrong 2022年11月17日，安斯泰来宣布Claudin18.2抗体 ...
佐妥昔单抗(Zolbetuximab) - 药物靶点：CLDN18.2_在研适应症：晚期胃食管交界处腺癌，CLDN18.2阳性胃食管交界处腺癌 ...
WO2022136642A1 - Tumor-specific claudin 18.2 antibody-drug conjugates ...
Claudin 18.2 (CLDN18.2) – A Tumour Immune Target for Solid‑Tumour ...
Claudin18.2靶点之争：安斯泰来搭台，国内药企唱戏-蓝鲸财经
安斯泰来：Claudin18.2抗体三期临床成功
Claudin18.2靶点至高点争夺战，一场有关实力和策略的较量-36氪
Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2 ...
Claudin18.2：肺癌胃癌新鉴
Efficacy and Safety of Zolbetuximab in Gastric Cancer
项目合作｜Claudin18.2×CD8+T双特异性抗体 01项目概况1、项目名称：Claudin18.2×CD8+ T双特异性抗体2、适应症 ...
A novel highly sensitive inner filter effect-based fluorescence ...
速递|FDA授予同时靶向Claudin 18.2和4-1BB的双特异性抗体药物TJ-CD4B胃癌孤儿药资格-无癌家园
CLDN18.2抗体突破性进展！安斯泰来Zolbetuximab在3期SPOTLIGHT试验中达到主要终点|恶性肿瘤|癌细胞|药品|肿瘤|-健康界
Zolbetuximab（佐妥昔单抗）治疗CLDN18.2阳性胃癌获美FDA优先审评！-印塔健康官网
安斯泰来公布首个CLDN18.2靶向药-Zolbetuximab联合CAPOX的III期临床数据_腾讯新闻
Full article: Characterization of zolbetuximab in pancreatic cancer models
全球首款胃癌Claudin18.2抗体Zolbetuximab（佐妥昔单抗、Vyloy）在日本获批上市！附说明书-临床试验 - 知乎
关于全球首款晚期胃癌靶向药CLDN18.2单抗Zolbetuximab（佐妥昔单抗、Vyloy）你想知道的都在这里！ - 知乎
Development and comparison of 68Ga/18F/64Cu-labeled nanobody tracers ...
Claudin18.2的结构、功能基础及其胃癌靶向药物的研发现状与挑战_生物器材网
Invitrogen Zolbetuximab Chimeric Recombinant Human Monoclonal Antibody ...
Zolbetuximab联合化疗治疗CLDN18.2阳性、HER2阴性胃癌临床数据公布！_患者_试验_包括
claudin18.2肿瘤靶向治疗的现状与未来
全球首款！信达生物Claudin18.2 ADC启动三期临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
FDA Gives Priority Review to Zolbetuximab in Advanced Gastric Cancer
Anti-CLDN18.2 hIgG1 Reference Antibody (IMAB362)
